Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ASCEND-I Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days

NCT01064388
View directory record Official record
Conditions
Healthy
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
23 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Results available

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

NCT02537873
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Lorcaserin, Cocaine Intravenous (IV), Placebo comparator
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 59 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

NCT02197975
View directory record Official record
Conditions
COPD
Interventions
PT010 Dose 1, PT010 Dose 2, Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ASKP1240 After a Single Intravenous Dose at Escalating Dose Levels in Healthy Subjects

NCT01565681
View directory record Official record
Conditions
Pharmacokinetics of ASKP1240, Healthy Volunteers
Interventions
ASP1240, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 5, 2026, 11:52 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

NCT04055168
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD6615, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 5, 2026, 11:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855
View directory record Official record
Conditions
Solid Tumours
Interventions
AZD4956, Saruparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New York, New York • Providence, Rhode Island • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

Effects of Triiodothyronine (T3) in Ischemic Heart Failure

NCT05384847
View directory record Official record
Conditions
Heart Failure
Interventions
Thyroid hormone T3, Control Group
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT03482648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868
View directory record Official record
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

NCT06311760
View directory record Official record
Conditions
Healthy Participants Study
Interventions
AZD0292, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry

NCT05351047
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD2373 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma

NCT00613691
View directory record Official record
Conditions
Carcinoma
Interventions
SPI-1620
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2013 · Synced Sep 5, 2026, 11:52 PM EDT
Terminated Phase 1 Interventional

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

NCT00351325
View directory record Official record
Conditions
Advanced Solid Malignancies
Interventions
BMS-663513
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.

NCT02106338
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Placebo, CRS3123
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers

NCT02596399
View directory record Official record
Conditions
Healthy Volunteer
Interventions
DSTA4637S, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

NCT03906006
View directory record Official record
Conditions
Gout, Hyperuricemia
Interventions
ABP-671, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

AZD9496 First Time in Patients Ascending Dose Study

NCT02248090
View directory record Official record
Conditions
ER+ HER2- Advanced Breast Cancer
Interventions
AZD9496
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Sarasota, Florida • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2019 · Synced Sep 5, 2026, 11:52 PM EDT
Terminated Early Phase 1 Interventional

Angiotensin-(1-7) in Peripheral Arterial Disease

NCT03240068
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Angiotensin 1-7, Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study of New Computer-based Neuropsychological Tool: Visual Tests, Touch Responses

NCT03502603
View directory record Official record
Conditions
Cerebral Neurological Illness
Interventions
Railroad Test, Swamp Test, Presidents Recognition Test, Judgment of Line Orientation, Symbol Span subtest of the Wechsler Memory Scale-IV, Information subtest of the Wechsler Adult Intelligence Scale-IV:, Digit Span subtest of the Wechsler Adult Intelligence Scale-I, Reading subtest of the Wide Range Achievement Test, Symbol Digit Modalities Test:, Dot Counting Test
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 5, 2026, 11:52 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy

NCT04046107
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
Cemiplimab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacodynamic Study of CD-NP

NCT00482937
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
CD-NP
Drug
Lead sponsor
Nile Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 5, 2007 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

NCT02926768
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Adenocarcinoma
Interventions
CK-101
Drug
Lead sponsor
Checkpoint Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Sarasota, Florida • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 5, 2026, 11:52 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

NCT05476497
View directory record Official record
Conditions
Peanut Allergy
Interventions
VLP Peanut, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 5, 2026, 11:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity

NCT06680440
View directory record Official record
Conditions
Weight Management
Interventions
ASC30, Placebo
Drug · Other
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Sep 5, 2026, 11:52 PM EDT